Here are some of the most influential advances in dementia research over the last century – thank you for helping to make them possible.
Non-drug approaches also hold real promise in limiting the devastating effects of dementia.
Pfizer’s move in January was a shifting in research and development priorities to move away from neurodegeneration research carried out in-house in favour of other areas of research, while continuing to invest in other avenues to support neurodegeneration research – like their continued support of the Dementia Discovery Fund.
I am happy to boast that I have been described as one of the best-studied people on the planet.
Clinical trials are research experiments or observations; studies involving people that are designed to answer questions about biomedical or behavioural aspects of disease. This may include investigating new treatments such as medicines, vaccines, dietary supplements and medical devices.
A highlight of the conference, in which so much was covered, was a presentation from Dr John Skidmore, Chief Scientific Officer at our Cambridge Drug Discovery Institute (DDI).
While we have known about the disproportionately high impact of dementia on women for some time, we’re not entirely clear of the reasoning behind these differences.
Recent news from the pharmaceutical industry that Pfizer is reducing its investment in dementia research has highlighted some of the barriers to research, and the increased need for shared responsibility in bringing treatments to people in need.
It is both a challenging and exciting time to be investigating the relationship between traumatic brain injury (TBI) and dementia. A recent surge in attention around the topic is welcome but links with the milder-end of head injury in sport have to be treated with caution.
At Alzheimer’s Research UK, we are celebrating what has been a busy, challenging and successful year. This has been particularly true for our policy and public affairs efforts as the past twelve months presented many opportunities for lawmakers to make dementia research a priority. With your help, we’ve gained ground. We’re taking a look back at the work we accomplished together in 2017.